Is AI Drug Discovery Actually Working? What the 2026 Clinical Trial Data Shows
Dr. Dereck Mush, MD, MBA
BenevolentAI
Employs an artificial intelligence platform to discover novel therapies for complex diseases.
What they do
BenevolentAI builds an end to end platform that ingests massive biomedical data to generate scientific insights. Their software helps research scientists identify target diseases, design new drug molecules, and predict patient responses to accelerate clinical development.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- AI drug discovery
- Product type
- Platform software
- Stage
- Public
- Headquarters
- London, United Kingdom
- Region
- Europe
- Founded
- 2013
- Total funding
- $300M raised
Notable investors: Temasek Holdings, Lansdowne Partners, Woodford Investment Management.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBAThe HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA